PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $362,740 | -92.0% | 21,747 | -86.8% | 0.00% | -88.9% |
| Q2 2023 | $4,543,489 | -85.5% | 164,500 | -88.0% | 0.01% | -86.6% |
| Q1 2023 | $31,419,840 | +98.0% | 1,366,080 | -6.1% | 0.07% | +86.1% |
| Q4 2022 | $15,868,006 | +131.0% | 1,454,446 | +78.5% | 0.04% | +140.0% |
| Q3 2022 | $6,869,000 | +87.1% | 814,726 | +75.6% | 0.02% | +87.5% |
| Q2 2022 | $3,671,000 | +63.5% | 464,057 | +435.3% | 0.01% | -20.0% |
| Q1 2021 | $2,245,000 | -4.6% | 86,691 | -25.8% | 0.01% | -23.1% |
| Q4 2020 | $2,354,000 | +989.8% | 116,794 | +556.2% | 0.01% | +550.0% |
| Q2 2019 | $216,000 | – | 17,799 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |